High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma

About 40% of patients with non–small cell lung cancer (NSCLC) have stage IV cancer at the time of diagnosis. The only viable treatment options for metastatic disease are systemic chemotherapy and immunotherapy. Nonetheless, chemoresistance remains a major cause of chemotherapy failure. New immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinod, Natasha, Hwang, Duhyeong, Azam, Salma H., Van Swearingen, Amanda E. D., Wayne, Elizabeth, Fussell, Sloane Christian, Sokolsky-Papkov, Marina, Pecot, Chad V., Kabanov, Alexander V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299629/
https://www.ncbi.nlm.nih.gov/pubmed/32596460
http://dx.doi.org/10.1126/sciadv.aba5542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299629/
https://www.ncbi.nlm.nih.gov/pubmed/32596460
http://dx.doi.org/10.1126/sciadv.aba5542

Ejemplares similares